Obesity pill Orforglipron data expected in April 2025: Eli Lilly exec

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-06-11T18:19:10+05:30 | Updated On 11 Jun 2024 6:19 PM IST

Eli Lilly Muvalaplin lowered an inherited form of high cholesterol in trial

London: Eli Lilly executive said that data from the late-stage trial of their experimental obesity pill, orforglipron, is anticipated to be released in April 2025.

The pill is part of a class of drugs known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow the rate at which the stomach empties of food and decrease appetite.

Drugs from the class are also being tested to treat Alzheimer's.

According to a Reuters report, Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman Sachs healthcare conference, said his company is not convinced that the drug will help with the disease itself, but might help with underlying conditions like obesity and stroke that lead to cognitive decline.

Read also: No major concerns raised by USFDA staff on Eli Lilly Alzheimer's drug Donanemab

Meidcal Dialogues team had earlier reported that Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, had collaborated with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.

eli lillyeli lilly newsobesity pillorforglipron

Source : with inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751